AR072265A1 - Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende - Google Patents
Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprendeInfo
- Publication number
- AR072265A1 AR072265A1 ARP090102266A ARP090102266A AR072265A1 AR 072265 A1 AR072265 A1 AR 072265A1 AR P090102266 A ARP090102266 A AR P090102266A AR P090102266 A ARP090102266 A AR P090102266A AR 072265 A1 AR072265 A1 AR 072265A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkenyl
- independently selected
- cycloalkyl
- groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Tiazolilo y oxazolilo isoquinolinonas sustituidas que actuan, por ejemplo, como moduladores de poli(ADP-ribosa) polimerasa (PARP). La presente también se relaciona con el uso en el tratamiento de varias enfermedades y trastornos como cáncer y enfermedades neurologicas. Reivindicacion 1: Un compuesto de formula 1 caracterizado porque: X es alquileno C1-9, alquenileno C2-9, o alquinileno C2-9; Y es O o S; R1, R2, R3, y R4 se seleccionan independientemente de hidrogeno, alquilo C1-6, halogeno, hidroxi, NH2, CN, perfluoroalquilo C1-6, CO2H, OR7, COOR7 o NHR7; R5 y R6 son cada uno, independientemente, hidrogeno, alquilo C1-6, alquenilo C2-4, cicloalquilo C3-7, fenilo o bencilo, en donde los grupos alquilo, alquenilo y anillo de los grupos cicloalquilo, fenilo y bencilo se sustituyen opcionalmente con uno o más grupos independientemente seleccionados de hidroxi, alcoxi C1-4, -CO2H, alcoxicarbonilo C1-6, NH2, mono o dialquilamino C1-6, o halogeno; o R5 y R6 junto con el nitrogeno al cual ellos se adhieren forman un anillo monocíclico o bicíclico heterocíclico de 3 a 12 miembros saturado, parcialmente insaturado o insaturado que comprende opcionalmente de uno a tres heteroátomos en el anillo adicionales independientemente seleccionados de N, O, o S, el resto de los átomos en el anillo son átomos de carbono; R7 es alquilo C1-6, alquenilo C2-6, o cicloalquilo C3-C en donde el alquilo, alquenilo, y anillos del cicloalquilo se sustituyen opcionalmente con uno o más grupos independientemente seleccionados de hidroxi, alcoxi C1-4, -CO2H, alcoxicarbonilo C1-6, NH2, mono o dialquilamino C1-6, o halogeno; o una forma de sal farmacéuticamente aceptable de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7385708P | 2008-06-19 | 2008-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072265A1 true AR072265A1 (es) | 2010-08-18 |
Family
ID=41087350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102266A AR072265A1 (es) | 2008-06-19 | 2009-06-19 | Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8299090B2 (es) |
| EP (2) | EP2896626A1 (es) |
| JP (2) | JP5564495B2 (es) |
| AR (1) | AR072265A1 (es) |
| AU (1) | AU2009260060B2 (es) |
| CA (1) | CA2728454C (es) |
| DK (1) | DK2303895T3 (es) |
| ES (1) | ES2530815T3 (es) |
| HK (2) | HK1156310A1 (es) |
| SA (1) | SA109300394B1 (es) |
| TW (1) | TWI471329B (es) |
| WO (1) | WO2009155402A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5632368B2 (ja) * | 2008-06-19 | 2014-11-26 | ワイス・エルエルシー | チエニル−およびフラニル−イソキノリノン、ならびにそれらの使用方法 |
| SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
| EP2729007A1 (de) | 2011-07-04 | 2014-05-14 | Bayer Intellectual Property GmbH | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| ES2562903T3 (es) * | 2011-07-13 | 2016-03-09 | Santen Pharmaceutical Co., Ltd | Nuevo compuesto que tiene actividad inhibidora de PARP |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0005745B1 (en) * | 1978-05-26 | 1982-07-14 | Gruppo Lepetit S.P.A. | Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| ES2376166T3 (es) * | 2002-11-22 | 2012-03-09 | Mitsubishi Tanabe Pharma Corporation | Compuestos de isoquinolina y su uso medicinal. |
| ATE533812T1 (de) | 2005-08-01 | 2011-12-15 | Wietek Holding Gmbh | Verfahren zur rezyklierung von kunststoff |
| EP2069351B1 (en) * | 2006-06-20 | 2015-10-28 | AbbVie Inc. | Pyrazoloquinazolinones as parp inhibitors |
| JP5632368B2 (ja) * | 2008-06-19 | 2014-11-26 | ワイス・エルエルシー | チエニル−およびフラニル−イソキノリノン、ならびにそれらの使用方法 |
| SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
-
2009
- 2009-06-17 SA SA109300394A patent/SA109300394B1/ar unknown
- 2009-06-18 DK DK09767711.6T patent/DK2303895T3/en active
- 2009-06-18 JP JP2011514801A patent/JP5564495B2/ja not_active Expired - Fee Related
- 2009-06-18 AU AU2009260060A patent/AU2009260060B2/en active Active
- 2009-06-18 EP EP14185672.4A patent/EP2896626A1/en not_active Withdrawn
- 2009-06-18 US US12/487,247 patent/US8299090B2/en active Active
- 2009-06-18 ES ES09767711T patent/ES2530815T3/es active Active
- 2009-06-18 CA CA2728454A patent/CA2728454C/en active Active
- 2009-06-18 EP EP09767711.6A patent/EP2303895B1/en active Active
- 2009-06-18 WO PCT/US2009/047767 patent/WO2009155402A1/en active Application Filing
- 2009-06-19 TW TW98120713A patent/TWI471329B/zh active
- 2009-06-19 AR ARP090102266A patent/AR072265A1/es active IP Right Grant
-
2011
- 2011-10-06 HK HK11110561.5A patent/HK1156310A1/xx unknown
-
2012
- 2012-10-18 US US13/655,082 patent/US8906935B2/en active Active
-
2014
- 2014-03-28 JP JP2014067493A patent/JP2014122242A/ja not_active Withdrawn
- 2014-11-07 US US14/535,877 patent/US9265769B2/en active Active
-
2016
- 2016-01-21 HK HK16100665.6A patent/HK1212698A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1156310A1 (en) | 2012-06-08 |
| US8299090B2 (en) | 2012-10-30 |
| JP2011525185A (ja) | 2011-09-15 |
| DK2303895T3 (en) | 2015-01-12 |
| AU2009260060B2 (en) | 2015-01-22 |
| JP5564495B2 (ja) | 2014-07-30 |
| AU2009260060A1 (en) | 2009-12-23 |
| CA2728454A1 (en) | 2009-12-23 |
| CA2728454C (en) | 2017-01-17 |
| TW201002725A (en) | 2010-01-16 |
| SA109300394B1 (ar) | 2013-01-22 |
| EP2303895A1 (en) | 2011-04-06 |
| US20130059843A1 (en) | 2013-03-07 |
| WO2009155402A1 (en) | 2009-12-23 |
| EP2896626A1 (en) | 2015-07-22 |
| TWI471329B (zh) | 2015-02-01 |
| US20150133443A1 (en) | 2015-05-14 |
| JP2014122242A (ja) | 2014-07-03 |
| ES2530815T3 (es) | 2015-03-05 |
| HK1212698A1 (zh) | 2016-06-17 |
| US9265769B2 (en) | 2016-02-23 |
| EP2303895B1 (en) | 2014-09-24 |
| US20090318442A1 (en) | 2009-12-24 |
| US8906935B2 (en) | 2014-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072265A1 (es) | Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende | |
| GT200500368A (es) | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| CO6410305A2 (es) | Inhibidores de poli (adp-ribosa) polimerasa (parp) | |
| CL2008001374A1 (es) | Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| AR064010A1 (es) | Inhibidores de la actividad de la akt | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
| PE20121556A1 (es) | 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina | |
| PE20130395A1 (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
| AR076707A1 (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR076794A1 (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen | |
| ECSP088122A (es) | Composiciones y métodos para el diagnóstico y el tratamiento de tumores | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| UY29197A1 (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos | |
| CR20140085A (es) | Inhibidores de pde10 de pirimidina | |
| AR068466A1 (es) | Cianoisoquinolina | |
| PE20130157A1 (es) | Inhibidores de la polimerasa virica | |
| ECSP088762A (es) | Tratamiento del dolor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |